【1月26日IPO雷达】北芯生命申购

Core Viewpoint - The article discusses the upcoming IPO of Beixin Life (科创板, 6887), highlighting its market position and financial performance in the cardiovascular intervention solutions sector. Group 1: Company Overview - Beixin Life is recognized as a leader in China's cardiovascular precision intervention solutions, focusing on clinical precision diagnosis for coronary artery diseases [2] - The company has a total market capitalization of 6.307 billion yuan and an issuance price of 17.52 yuan per share [2] - The controlling shareholder, Dr. Song Liang, has over 18 years of relevant R&D experience and the core products have received multiple certifications and awards [2] Group 2: Product and Market Position - The core product, the FFR measurement system, held a 30.6% market share in the domestic coronary indication market, ranking second with a 10.4% overall market share [2] - The product pipeline includes seven ongoing projects, with the pulse electric field ablation system currently in clinical trials [2] Group 3: Financial Performance - The company reported revenues of 318 million yuan for 2024, reflecting a 72.09% increase [3] - In the past three years, the company's revenue has shown significant growth: 184 million yuan in 2023 (+99%), and 92 million yuan in 2022 (+78.61%) [3]